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Original articleChemotherapy cardiotoxicity: cardioprotective drugs and
early identification of cardiac dysfunction
Daniela Di Lisia, Giuseppe Leggioa, Giuseppe Vitalea, Salvatore Arrottia,
Rosanna Iaconaa, Riccardo Maria Inciardia, Domenico Nobilea,
Francesca Bonuraa, Giuseppina Novoa, Antonio Russob and Salvatore NovoaBackground Chemotherapy cardiotoxicity is an emerging
problem and it is very important to prevent cardiac
dysfunction caused by anticancer drugs. The aim of this
study was to assess the alterations of the cardiac function
induced by chemotherapy in a follow-up of 2 years and to
evaluate the cardioprotective role of angiotensin-converting
enzyme inhibitors (ACEIs) in the prevention of cardiac
dysfunction.
Methods A prospective study was carried out using
patients with breast cancer (85 women; median age
57W12 years) and other inclusion and exclusion criteria. On
the basis of treatment, patients were divided into six groups:
fluorouracil-epirubicincyclophosphamide, FEC (group A);
FEC and trastuzumab (B); trastuzumab (C); FEC and
taxotere (D); FEC, paclitaxel and trastuzumab (E); and
chemotherapy and cardioprotective drugs (F). Cardiological
evaluation including electrocardiogram and conventional
echocardiogram with tissue Doppler imaging (TDI) was
carried out at T0 (before starting chemotherapy), T1 (after
6months from the start of chemotherapy) and T2 (2 years
after the end of chemotherapy).
Results Significant changes in the TDI parameters of
systolic and diastolic function were observed at T1 and T2 inopyright © Italian Federation of Cardiology. Una
1558-2027  2014 Italian Federation of Cardiologyall patients. A significant reduction of left ventricular ejection
fraction (LVEF) was observed only at T2. In the patients
treated with ACEI (F), these changes were less significant
than in other groups and they do not have significant
changes in the indices of diastolic function.
Conclusion TDI is more sensitive than conventional
echocardiogram in the early diagnosis of cardiac
dysfunction and ACEIs seem to have an important role in the
prevention of cardiotoxicity.
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Chemotherapy cardiotoxicity is an emerging problem.
Some drugs, such as anthracyclines and other biological
agents, can cause cardiovascular complications (left ven-
tricular dysfunction, heart failure, myocardial ischemia,
hypertension, arrhytmias, pericarditis, cardiac tampo-
nade).1 Anthacycline-induced cardiotoxicity has been
categorized into acute, early-onset chronic progressive
and late-onset chronic progressive.2 Late anthracycline
cardiotoxicity is cumulative, dose related and high
dosages can result in congestive heart failure and left
ventricular dysfunction.3 Usually, cardiac damage caused
by anthracycline is irreversible (Type I cardiotoxicity).
Trastuzumab induces predominantly reversible dysfunc-
tion (Type II cardiotoxicity).4 This classification system
does have limitations; for example, trastuzumab, a Type
II drug, can trigger irreversible cardiac damage in patients
with severe preexisting cardiac disease or potentiate
anthracycline Type I cardiotoxicity. In Type I cardio-
toxicity, usually pathophysiology is related to cell loss,and in Type II, cellular dysfunction (mitochondrial and
protein alterations) underlies the reversible damage.5
Thus, it is very important that the early diagnosis of left
ventricular dysfunction induced by anticancer drugs
using tissue echocardiographic parameters [such as tissue
Doppler imaging (TDI) and speckle tracking] is more
sensitive than conventional echocardiography and the
prevention of severe forms of cardiac dysfunction using
early cardioprotective drugs [such as angiotensin-
converting enzyme inhibitor (ACEI), angiotensin recep-
tor blockers (ARBs) and beta-blockers] when subclinical
cardiotoxicity has been identified.6
The aim of this study was to assess the alterations of the
cardiac function induced by chemotherapy in a follow-up
of 2 years (using conventional echocardiographic
parameters associated with tissue Doppler parameters)
and to evaluate the protective role of drugs (ACEI, ARBs
and beta-blockers) in the prevention of severe forms of
cardiac dysfunction.uthorized reproduction of this article is prohibited.
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Table 1 Patients studied
Number of patients
Total number 85
Age 5712
Family history of cardiovascular disease 51 (60%)
Diabetes 13 (15%)
Hypertension 38 (44%)
Obesity 9 (10%)
Dyslipidemia 13 (15%)
Smoking 16 (19%)Materials and methods
This study was designed and conducted as a prospective
study using 85 patients [85 women, mean age (SD)
57 12 years] with breast cancer treated with antineoplas-
tic agents. Patients were treated at University Hospital of
Palermo, Department of Medical Oncology, and several
criteria of inclusion and exclusion were used to recruit
patients. Inclusion criteria were early stage of disease
(presence of lymph nodes metastases but absence of
distantmetastases), anyhistological cancer, treatmentwith
anthracyclines [regimen fluorouracil–epirubicin–cyclo-
phosphamide (FEC), taxanes (taxol, taxotere) and trastu-
zumab], left ventricular ejection fraction (LVEF) of more
than 50% at baseline, normal indices of hepatic and renal
function, absence of major known diseases, availability of
patients to perform periodic electrocardiograms and echo-
cardiograms during follow-up at University Hospital of
Palermo, Department of Cardiology. Exclusion criteria
were presence of known heart disease, prior exposure to
mediastinal irradiation and earlier chemotherapy (factors
that increase the risk of cardiotoxicity). All patients had
cardiovascular risk factors such as hypertension (44%)
treated with ACEIs, ARBs and beta-blockers, diabetes
(15%), obesity (10%), cardiovascular familiarity (60%),
dyslipidemia (15%) and cigarette smoke (19%) (Table 1).
Patients treated with ACEIs were 64% of the population,
20% with ARBs and 16% with ß-blockers (Fig. 1).
On the basis of chemotherapy treatment and concomitant
treatment with ACEI, ARBs and beta-blockers, patients
were divided into six groups: A, six cycles of FEC; B,
three cycles of FEC and three cycles of trastuzumab; C,
six cycles of trastuzumab; D, three cycles of FEC andpyright © Italian Federation of Cardiology. Unau
Fig. 1
ACEi
β-blockers
ARBs
Patients treated with angiotensin-converting enzyme inhibitor, beta-
blockers and angiotensin receptor blockers.three cycle of taxotere; E, three cycles of FEC and three
cycles of taxol and trastuzumab; and F, chemotherapy
and ACEI/ARBs/ß-blockers (Table 2). Cardiological
evaluation including electrocardiogram and echocardio-
gram was made at baseline (T0), at 6 months after the
start of chemotherapy (T1) and at 2 years after the end of
chemotherapy. The median length of chemotherapy was
1 year.
Echocardiographic evaluation was carried out by means
of echocardiographic machine Acuson. Chamber dimen-
sion, LVEF and systolic function, valve function and
morphology, Doppler pattern and diastolic function were
assessed with conventional echocardiography.
Parameters of conventional echocardiography were inte-
grated with tissue Doppler parameters.
Echocardiographic evaluation considered LVEF, E/A
and TDI [Em/Am¼ ratio between myocardial early dias-
tolic velocity (Em) and myocardial atrial velocity (Am);
myocardial systolic velocity (Sm), isovolumic relaxation
time (IVRT), isovolumic contraction time (IVCT) and
global performance index (TEI)]. LVEF was measured
by a modified biplane Simpson method. E/A ratio was
measured with standard Doppler. Em, Am and Sm were
obtained with TDI by placing the sample volume at
mitral annulus lateral, at the junction between the left
ventricular lateral wall and mitral annulus, in the apical
four-chamber section. The TDI parameters were always
measured by the same investigator.
Statistical methods
Data are reported as mean standard deviation SD.
Differences between values measured at different times
(T0, T1, T2) were assessed using Student’s t-test and
were considered significant for a P value less than 0.05.
Results
During echocardiographic follow-up, we did not find sig-
nificant reductions in LVEF at T1, but we found signifi-
cant changes at T2 (62% 0.15 at baseline, 60% 0.08 at
T2, P< 0.0001) when considering the patient population
as a whole.
Conversely, significant changes in the tissue Doppler
parameters of systolic function (Sm and IVCT) werethorized reproduction of this article is prohibited.
Table 2 Groups
Group Number of patients Mean age Chemotherapy
Group A 14 (16%) 599 FEC
Group B 14 (16%) 556 FEC and trastuzumab
Group C 15 (18%) 6215 Trastuzumab
Group D 36 (43%) 548 FEC and taxotere
Group E 6 (7%) 6320 FEC and taxol and
trastuzumab
Group F 38 (44%) 667 Chemotherapy and
ACEi/ARBs/b-blockers
ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor
blockers; FEC, regimen fluorouracil–epirubicin– cyclophosphamide.
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Table 3 Changes in Em and Sm
Sm (P) Em (P)
T0 14.433.21 15.783.7
T1 122.15 (P<0.0001) 14.382.3 (P¼0.003)
T2 11.902.21 (P<0.0001) 12.193.05 (P<0.0001)
Fig. 3
Table 4 Changes in E/A and Em/Am
E/A P Em/Am P
T0 1.050.24 0.880.23
T1 0.950.19 0.003 0.800.12 0.005
T2 0.930.24 0.001 0.780.15 0.001observed not only at T2 but also early at T1 in the whole
population. Sm decreased significantly at T1 and T2
(Table 3). IVCT was significantly increased in the gen-
eral population at T1 and T2 (Fig. 2).
A significant reduction was found in the E/A ratio and in
the Em/Am ratio, but the Em/Am ratio measured with the
tissue Doppler was more sensitive than the E/A ratio in
showing the early presence of diastolic dysfunction at
baseline and after chemotherapy because in 65% of the
population, Em/Am inversion at T1 preceded E/A inver-
sion at T2 (Table 4). Significant changes were found in
Em and Am at T1 and T2 (Table 3). IVRT measured
with the tissue Doppler and TEI index showed a signifi-
cant increase at T1 and T2.
TEI index, a parameter of global left ventricular function,
was found significantly increased at T1 (0.36 0.09 at T0,
0.47 0.13 at T1, 0.54 0.09 at T2, P< 0.05) in the whole
population (Fig. 3). Evaluation of patients within several
groups (A, B, C,D, E, F) showed significant changes in the
echocardiographic parameters of systolic function and
diastolic function in some groups, but not in all groups.
In group A (14 patients, mean age 59 9 years), we found
significant changes in the echo parameters of systolic and
diastolic function. Sm showed a significant reduction at
T1 and T2 and LVEF showed a significant reduction at
T2 but not at T1 (Table 5).
IVRT and TEI index were increased significantly at T1
and T2. The E/A ratio and the Em/Am ratio were
significantly reduced at T1 and T2.
In the other groups (B, C, D, E), changes in the TDI
indices have been less significant than the same indices inopyright © Italian Federation of Cardiology. Una
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Changes in isovolumic relaxation time and isovolumic contraction time
in the whole population.group A and changes in the echo parameters followed the
same trend as the whole population. Maybe in A group,
the alterations were more significant because these
patients were treated with a high dose of anthracyclines
compared with other groups and anthracycline cardio-
toxicity is dose related.
Additional and important observations were made in F
group. In this group, significant changes in the echo
parameters of systolic function were found. Sm showed
a significant reduction at T1 and T2. IVCT has increased
significantly at T1 and T2 (Table 6).
The TEI index showed a significant increase at T1 and
T2. These modifications of systolic function parameters
were less significant than those found in the general
population and in the subgroup of patients who are not
treated with antihypertensive drugs. In addition, for this
group, we did not find significant changes in the echo
parameters of diastolic function at T1 andT2 (IVRT, E/A
ratio and Em/Am ratio). We did not find significant
changes in LVEF at T1 and T2 (Table 6). We evaluated
the intra-observer variability that was not
statistically significant.
Discussion
Chemotherapy cardiotoxicity is an emerging problem and
the early diagnosis of left ventricular dysfunction induced
by anticancer drugs using tissue echocardiographic
parameters (such as TDI and speckle tracking) is very
important to prevent the development of severe forms ofuthorized reproduction of this article is prohibited.
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Changes in global performance index in the whole population. ACEI,
angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor
blockers; FEC, regimen fluorouracil–epirubicin–cyclophosphamide;
Group A, six cycles of FEC; Group B, three cycles of FEC and three
cycles of trastuzumab; Group C, six cycles of trastuzumab; Group D,
three cycles of FEC and three cycles of taxotere; Group E, three cycles
of FEC, three cycles of taxol and trastuzumab; Group F, chemotherapy
and ACEI/ARBs/ß-blockers; IVCT, isovolumic contraction time; IVRT,
isovolumic relaxation time; Sm, Em and Am, tissue Doppler imaging
parameters; TEI index, global performance index.
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Table 5 Changes in systolic function in A group
Sm P LVEF P
T0 14.92.95 620.15
T1 12.030.5 <0.05 620.10 >0.05
T2 11.71.87 <0.05 600.08 <0.0001
LVEF, left ventricular ejection fraction.cardiac dysfunction, using cardioprotective agents early,
when subclinical dysfunction is detected.
Our results are in agreement with the literature data and
confirmed by the results reported in our previous work,
but various important novel findings were demonstrated.7
For example, limited data are present in the literature
regarding the correlation between the early identification
of cardiac dysfunction detected by TDI and clinical
dysfunction detected by LVEF. In our study, we found
a significant reduction in the LVEF only at T2 and not at
T1. A significant reduction in the TDI parameters of
systolic function was observed not only at T2 but early at
T1. Thus, TDI parameters are more sensitive in the early
diagnosis of left ventricular dysfunction than LVEF and
the monitoring of TDI parameters would be used during
chemotherapy treatment such as integration to conven-
tional echocardiography. Several studies demonstrated
the superiority of TDI compared with LVEF in the early
diagnosis of left ventricular dysfunction.8–10 Thus, our
study confirms that significant changes in the TDI echo
parameters predict the later occurrence of cardiotoxicity
and the later reduction of LVEF.
It is demonstrated that longitudinal dysfunction is the first
subclinical step towards a further degree of myocardial
deterioration. Longitudinal left ventricular mechanics are
predominantly governed by the subendocardial layer,
which are the most vulnerable and most sensitive to the
presence of myocardial disease, ischemic heart disease as
well as cardiomyopathy induced by drugs.11
In the subendocardium, the fibres are roughly longitudin-
ally oriented, with an angle of about 808with respect to the
circumferential direction.The angledecreases towards the
midwall, wherein the fibres are oriented in the circumfer-
ential direction (08) and decrease further to an oblique
orientation of about –608 in the subepicardium.12
Thus, TDI evaluating mitral annulus velocity and the
global longitudinal left ventricular function is more sen-
sitive than ejection fraction in the early diagnosis of leftpyright © Italian Federation of Cardiology. Unau
Table 6 Changes in E/A, Em/Am, isovolumic relaxation time and Sm
E/A (P) Em/Am (P)
T0 0.80.17 0.820.13
T1 0.80.2 (P¼1) 0.80.12 (P¼0.48)
T2 0.790.19 (P¼0.8) 0.80.02 (P¼0.35)
IVRT, isovolumic relaxation time.ventricular dysfunction induced by anticancer drugs
(Table 7).
In addition, we found that oncological patients treated
with ACEI, ARBs and beta-blockers compared with the
whole population showed less significant changes in the
TDI parameters of systolic function (Sm and IVCT) at
T1 and T2. LVEF did not show a significant decrease in
this group and diastolic impairment did not occur (E/A
and Em/Am ratio did not change significantly). Thus, our
data confirm and support previous studies about the
cardioprotective role of ACEI in the chemotherapy car-
diotoxicity.13 ACEIs reduce afterload and systolic ven-
tricular wall stress, increase cardiac output, improve
ventricular geometry, prevent the growth effects of
angiotensin II on myocytes, attenuate aldosterone-
induced cardiac fibrosis and reduce apoptosis of cardiac
cells.14 In animal models, cardiac ACE activity was found
to be increased after chemotherapy compared with con-
trol individuals. Notably, treatment with lisinopril started
after chemotherapy significantly inhibited cardiac ACE
activity and improved mortality, cardiac remodelling and
cardiac dysfunction in an animal model. A previous
study15 demonstrates that in rats treated with temocapril,
collagen accumulation was inhibited and fibrosis was
avoided in the cardiac interstitium.
Thus, these findings suggest that beneficial effects of
ACEI in anthracycline-treated animals depend on inhi-
bition of cardiac ACE and that its activation plays a
pivotal role in the development of this kind of cardio-
myopathy. ACEIs have been shown to be potent scaven-
gers of free radical and they exert antioxidant effects.16
Other studies showed a protective effect of ARBs after
treatment with anthracyclines, which was demonstrated
in rats; it was shown that pretreatment with the ARBs
elicited a normalization of significant biochemical
parameters and reduced cardiac tissue damage.17,18
ACEI, beta-blockers and angiotensin II receptor block-
ers seem to prevent the development of late cardio-
toxicity in patients treated with high doses of
chemotherapy.13,19,20
A recent study21 showed an improvement of global
longitudinal strain in cancer patients treated with beta-
blockers. Thus, the early diagnosis of cardiotoxicity is
very important to prevent the development of late car-
diotoxicity and heart failure using cardioprotective agents
such as ACEI, beta-blockers and ARBs.thorized reproduction of this article is prohibited.
in F group
IVRT (P) Sm (P)
6410 153
6619 (P¼0.057) 13.91.5 (P¼0.047)
7017 (P¼0.06) 12.943.14 (P¼0.0046)
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Table 7 Differences between A group and F group
A group F group
Sm (P) LVEF (P) Sm (P) LVEF (P)
T0 14.92.95 620.15 153 620.15
T1 12.030.5 (P¼0.030) 620.10 (P>0.05) 13.91.5 (P¼0.047) 620.10 (P>0.05)
T2 11.71.87 (P¼0.002) 600.08 (P<0.0001) 12.943.14 (P¼0.0046) 620.22 (P>0.05)
LVEF, left ventricular ejection fraction.But further study is necessary. European Society for
Medical Oncology (ESMO) clinical practice guidelines
recommend serial evaluation of LVEF and the start of
treatment with enalapril when there is a significant
reduction of ejection fraction (LVEF) and in the patients
with subclinical cardiotoxicity induced by Type I agents
also identified by an increase in cardiac troponin.22 How-
ever, it would be desirable to start cardioprotective
therapy in all patients with subclinical cardiotoxicity
identified by new echocardiographic parameters.
Study limitation
The main limitation of the study was the number of
patients included in the study, especially the number of
patients treated with ACEI and ARBs. Furthermore, a
larger population will be necessary in the future. Another
limitation of the study was the use of TDI without the
assessment of left ventricular longitudinal strain.23 TDI
represents a good, easy and reliable method to measure
left ventricular longitudinal performance, particularly in
the early phases of cardiac toxicity from chemotherapy.
However, it is a Doppler technique and its main intrinsic
limitation is represented by the angle dependency.
Conversely, two-dimensional (2D) speckle-tracking
echocardiography (STE) is a relatively new, largely
angle-independent technique used for the evaluation
of myocardial function. Strain describes myocardial
deformation that is the fractional change in the length
of a myocardial segment. Strain and strain rate analysis
increases sensitivity in detecting subclinical cardiac
involvement in conditions such as amyloidosis, diabetes
and hypertensive heart disease, as well as changes in left
ventricular function after cancer treatment.24 Assessment
of 2D strain by STE is a semiautomatic method, which
requires manual definition of the myocardium. Training
and experience are needed for proper interpretation and
recognition of artifacts.25 We have not used 2D STE in
our study because we evaluated cardiac dysfunction
induced by anticancer agents in a follow-up of 3 years
(2 years after the end of chemotherapy with median
length of treatment 1 year), and 3 years ago at baseline
in our central hospital, adequate software for the assess-
ment of left ventricular longitudinal strain was not avail-
able. Another limitation of the study was not dose cardiac
biomarkers such as T-Brain natriuretic peptide (T-BNP)
and Troponin. The role of biochemical markers is still
controversial in literature; however, the dosage ofopyright © Italian Federation of Cardiology. UnaTroponin and T-BNP is quite accepted in the early
detection of cardiac damage, particularly if it is associated
with imaging techniques.26–29
In our study, dosage of T-BNP and Troponin levels was
not available because serial dosages were needed and
patients had poor compliance. Furthermore, in the
future, it is necessary to correlate biomarker levels,
TDI, strain and cardioprotective role of drugs in long-
term follow-up for the early diagnosis of cardiotoxicity.
Conclusion
TDI is more sensitive than LVEF in the early diagnosis
of left ventricular dysfunction and it may help target
patients who could benefit from closer cardiac monitor-
ing, earlier initiation of cardioprotective medical therapy
or less cardiotoxic novel tyrosine kinase inhibitors and
anticancer drugs. In addition, ACEI, ARBs and beta-
blockers have a cardioprotective role in the prevention
of chemotherapy cardiotoxicity.
Thus, patients with subclinical cardiotoxicity detected
using TDI and significant changes in the echo parameters
of systolic and diastolic function, during chemotherapy
and during follow-up, would start cardioprotective treat-
ment with ACEI or ARBs to prevent the development of
severe forms of cardiac dysfunction after chemotherapy.
Further studies are needed to support the use of these
drugs when subclinical cardiotoxicity is detected by new
echocardiographic parameters.
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